biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s): BIOAF

Healthcare Biotechnology

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.

TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > call me crazy but ill take on a bit more risk at this level

<< Previous

Bullboard Posts

Next >>

Comment by prophetoffactzon Dec 19, 2022 10:07am

116 Views

Post# 35179415

RE:call me crazy but ill take on a bit more risk at this level

Good luck. Let's see if they can close the deal in a potential very difficult market.

Webinar tommorrow.
The J&J xB3 option expires in about 30 business days.

Looks like some clinical data within about one month:

"In addition, the company expects to report data in the next couple of months from the second Phase I study assessing MTX110 in DIPG, conducted by Columbia University." Edison Group November 15
Midatech Pharma - Patient recruitment begins in rGBM study | Edison (edisongroup.com)

<< Previous

Bullboard Posts

Next >>

Quantum eMotion leaps by 20 per cent after Becton Dickinson deal